Pharmaceutical company specializing in identifying and developing clinical-stage compounds for orphan diseases and other diseases with unmet needs Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announced having completed psychotherapy training for a phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders.
The phase 2a clinical trial will be conducted at the University of Florida. The psychotherapy training was conducted by Fluence which is led by psychotherapists and researchers with massive experience in psychedelic clinical trials.
Fluence is also a leading provider of psychotherapeutic training for health professionals engaging in administration of psychedelic compounds to patients.
Tryp hopes that both the psychological and pharmaceutical will play a very important role in determining the outcomes for an oral formulation of synthetic psilocybin TRP-8802.
Tryp, University of Florida and Fluence have entered into an agreement to conduct a comprehensive training manual for the psychotherapy portion of Tryp’s psychedelic treatment which will be adapted for subsequent clinical trials.
“We continue to be amazed by the complexity of neural networks and the array of biological and behavioral factors that influence the healthy functioning of the brain and body. Our partners at the University of Florida have shown tremendous commitment to the effective administration of psychotherapy for our upcoming Phase 2a clinical trial, and Fluence continues to be an exceptional partner for the design and implementation of this important component of our therapies. The completion of this psychotherapy training marks a significant milestone for Tryp, as it remains an integral part of our novel treatment,” said Tryp’s Chief Science Officer, Jim Gilligan.